Understanding FMTVDM FRONTIER: A Guide for Select Nations
- Richard M Fleming, PhD, MD, JD
- Sep 3
- 4 min read
Updated: Oct 25
In today's fast-paced world, understanding the complexities of technology is crucial. One such technology that has gained attention is FMTVDM, or the Fleming Method for Tissue and Vascular Differentiation and Metabolism. This guide aims to break down the essentials of FMTVDM, making it accessible for readers from select nations.
FMTVDM is not just a technical term; it represents a significant scientific and medical advancement that measures changes in human health and disease. FMTVDM can additional determine which treatments work and which do not; saving time, money and most importantly - lives.
What is FMTVDM?
FMTVDM stands for the Fleming Method for Tissue and Vascular Differentiation and Metabolism. It is a patented method (U.S. Patent No. 9566037B2) that makes it possible to accurately diagnose health problems from their early changes through end stage disease, using currently available diagnostic imaging equipment. This patented method measures changes in regional metabolism and blood flow which differentiates healthy tissue from diseased tissue.
The primary goal of FMTVDM is to optimize patient care and management. It does this by accurately measuring what is and isn't happening inside the human body. The application of FMTVDM FRONTIER will ultimately extend to all living animals once the human database is fully completed and implemented.
Correcting for Errors Present in Current Nuclear Imaging Camera Systems
To correct inherent errors present in current nuclear camera systems, FMTVDM begins by calibrating and standardizing the nuclear imaging devices thereby tailoring each camera for the patient and specific health problems being considered including heart disease, cancer, infectious disease, et cetera. FMTVDM is not limited to a type of camera, or health problem but rather is calibrated and standardized based upon the camera type, isotope being used and the specific health problems that might be of concern. FMTVDM FRONTIER has adapted this to entire body evaluation (diagnostics and theranostics) independent of the question posed or equipment used.
(1) Nuclear Camera Calibration.
The first step requires that the camera be calibrated. Like each measuring tool, the camera must be calibrated to make certain it is accurate, consistent and reproducible. Currently utilized quality control (QA) does not do this. Currently utilized QA attempts to assure uniformity but uniformity of what is a major question.
(2) Enhancement of FMTVDM FRONTIER.
This step guarantees that the blood flow and the isotope are delivered to areas with the greatest regional metabolism and blood flow. Specific calibrations for coronary artery blood flow and assessment of cardiac viability follows this procedure in addition to the proprietary equations and A.I.2 software.
(3) FMTVDM FRONTIER Quantification.
The isotope emissions are then measured. These measurements distinguish between areas of infection, inflammation, cancer, heart disease and other health problems. While readily recognizable visual images are produced; which patients, physicians and researchers can look at, the FMTVDM measurements are what actual matter as they determine the state of health or disease present in the body. This removes bias, errors and life threatening mistakes.
(4) Derivation of coronary blood flow.
This requires the use of quantitative measurements in addition to several proprietary flow reserve equation which is part of FMTVDM FRONTIER A.I.2 package.
(5) Measuring Treatment response.
Once FMTVDM FRONTIER calibration, enhancement, quantification and application of A.I.2 proprietary equations and methods have been completed, patient treatment can be initiated. Following a period of treatment, FMTVDM FRONTIER imaging can be repeated and the resulting measured outcomes can be compared with the prior pretreatment or earlier treatment results, thereby allowing an objective measured determination of treatment success.
This same approach can be used to determine if drugs or other treatments undergoing review should be granted approval by the governmental regulatory agencies. This single aspect of FMTVDM FRONTIER will reduce government agency and corporate research costs while streamlining throughput of future treatments - both preventive and therapeutic.
Getting Started with FMTVDM FRONTIER
Countries interested in exploring FMTVDM FRONTIER further should complete the following steps.
Confirm Interest: Nations interested in participating in the Select Nation Status (SNS) program are encouraged to communicate directly with the Director of the FMTVDM Consortium via the following email: FMTVDM2025@gmail.com.
Participation of SNS Country Experts: Following the signing of the Non-disclosure agreement (NDA) by government officials, SNS country applicants should schedule an in-person presentation through the Public Relations/Management Team. During the FMTVDM FRONTIER presentation, countries are expected to collectively bring their experts in the fields of research, nuclear imaging, health care and their respective university and government agencies; to ask applicable questions to determine eligibility for SNS status.
FMTVDM FRONTIER SNS Pilot Programs: Following the signing of the FMTVDM FRONTIER licensing contract, the Director of FMTVDM Consortium will work directly with each SNS country and each selected FMTVDM FRONTIER imaging site, to initiate and carry out the 5-year program. Thus making each selected SNS country a Global Scientific and Medical Leader.
Gather Feedback: Once implemented, FMTVDM FRONTIER will gather feedback from each SNS country to continuously improve the service.
By taking these steps, you can effectively explore the potential of FMTVDM FRONTIER in your country.
Final Thoughts
FMTVDM FRONTIER represents a paradigm shifting advancement in medical diagnostics and theranostics for the countries selected.
As we move forward, it is essential to stay informed about developments in this field. By understanding FMTVDM FRONTIER and its applications, we can better prepare for a future where the practice of medical science, treatment of patients, and healthcare is changed forever.
